Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids

被引：0
|
作者：
Talaulikar, Vikram Sinai [1 ]
Manyonda, Isaac [1 ]
机构：
[1] St Georges Hosp & Univ London, London SW17 0RE, England
来源：
WOMENS HEALTH | 2014年 / 10卷 / 06期
关键词：
fibroids; medical; myoma; SPRM; ulipristal acetate;
D O I：
10.2217/WHE.14.60
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
Although it has been known for a long time that uterine fibroids respond to changes in sex steroid concentrations, it is the availability of selective progesterone receptor modulators such as ulipristal acetete that has provided the gynecologist with a novel option for medical management of uterine fibroids. Ulipristal acetate is presently licensed in Europe for use in women with symptomatic fibroids up to 3 months prior to surgery and has demonstrated good clinical efficacy and safety for this indication. Future trials will define the long-term safety of this drug and its role in medical management of uterine fibroids.
引用
收藏
页码：565 / 570
页数：6
相关论文
共 50 条
  • [21] Ulipristal Acetate Versus Leuprolide Acetate for Uterine Fibroids EDITORIAL COMMENT
    不详
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2013, 68 (02) : 99 - 100
  • [22] Treatment of Symptomatic Uterine Fibroids with Ulipristal Acetate: Endometrial Safety
    Catherino, William
    Eisenhut, Carol
    Blakesley, Rick
    Chan, Anna
    Sniukiene, Vilma
    Goldstein, Steven
    MODERN PATHOLOGY, 2017, 30 : 279A - 279A
  • [23] The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids
    Pohl, Oliver
    Zobrist, R. Howard
    Gotteland, Jean-Pierre
    REPRODUCTIVE SCIENCES, 2015, 22 (04) : 476 - 483
  • [24] Ulipristal acetate versus GnRH agonists in the treatment of uterine fibroids
    Ene, G.
    Albu, S.
    Stoian, R.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 122 : 75 - 76
  • [25] THE RETINOIC ACID PATHWAY IN UTERINE FIBROIDS IS NOT AFFECTED BY ULIPRISTAL ACETATE
    Roura-Monllor, Jaime A.
    Britten, Joy
    Driggers, Paul
    Malik, Minnie
    Catherino, William H.
    FERTILITY AND STERILITY, 2023, 120 (04) : E316 - E316
  • [26] Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids
    Tafi, Emanuela
    Scala, Carolina
    Maggiore, Umberto Leone Roberti
    Bizzarri, Nicolo
    Candiani, Massimo
    Venturini, Pier Luigi
    Ferrero, Simone
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (06) : 965 - 977
  • [27] Allergan: FDA Accepts NDA for Ulipristal Acetate for Uterine Fibroids
    Fiorentino, Desiree G.
    OBSTETRICS AND GYNECOLOGY, 2018, 131 (01): : 161 - 162
  • [28] Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids
    Biglia, Nicoletta
    Carinelli, Silvestro
    Maiorana, Antonio
    D'Alonzo, Marta
    Lo Monte, Giuseppe
    Marci, Roberto
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 8 : 285 - 292
  • [29] The Clinical Pharmacology and Pharmacokinetics of Ulipristal Acetate for the Treatment of Uterine Fibroids
    Oliver Pohl
    R. Howard Zobrist
    Jean-Pierre Gotteland
    Reproductive Sciences, 2015, 22 : 476 - 483
  • [30] Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids
    Ferrero, Simone
    Vellone, Valerio Gaetano
    Barra, Fabio
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2018, 14 (01) : 107 - 116
12345